Experts from AMCP emphasize the importance of drug-adjacent early detection tests and screening ability to improve patient ...
Outcome-weighted metrics (mortality, 5-year survival, MIR) better capture unmet need than incidence alone when assessing ...
Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending. In this Q&A, Urick discusses the ...
LaShawn McIver, MD, MPH, discusses a new report from a task force aiming to cut chronic disease prevalence 10% by 2035 through prevention and coordinated care.
LaShawn McIver, MD, MPH, discusses a new report from a task force aiming to cut chronic disease prevalence 10% by 2035 ...
Daryl Pritchard, PhD, discusses the challenges to implementing biomarker testing that would advance precision medicine and ...
Genomic profiling enables therapy individualization when actionable mutations (FLT3, NPM1, IDH1/2, TP53) are present, moving ...
At AMCP 2026, Kelsea Aragon, PharmD, discussed PrEP coverage, long-acting injectables, and payer strategies to improve HIV ...
Quality metrics for screening tests must evolve to mandate diagnostic resolution, ensuring financial and clinical incentives ...
CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina ...
Health systems and community practices strongly endorse partnership models, including after-hours triage, clinical training, ...
CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08512 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results